UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ Commission File Number: 001-38753 Moderna, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 81-3467528 (State or Other Jurisdiction o ...

With a background as an RN and an MBA, Stephen analyzes healthcare and tech stocks by combining clinical insight with rigorous valuation methods. He specializes in scenario-based DCF modeling, sensitivity analysis, and Monte Carlo simulations to uncover asymmetric risk-reward. His focus is on translating complex science and market dynamics into actionable investment theses. His influences include Superforecasting and Fooled by Randomness.Stay up to date with Stephen's latest thoughts and investment insights ...

Moderna Inc. MRNA reported on Thursday a first-quarter EPS loss of $(2.52), missing the consensus of $(3.12), down from an EPS loss of $(3.07) a year ago.The COVID-19 vaccine maker reported quarterly sales of $108 million, down from $167 billion a year ago, beating the consensus of $106.20 million.The decline was primarily driven by lower net product sales, which totaled $86 million in the quarter.The reduction in product sales reflects lower vaccination rates compared to the same period last year and the c ...

Moderna (MRNA) incurred a loss of $2.52 per share in the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $2.92. In the year-ago period, the company had reported a loss of $3.07.Total revenues in the quarter were $108 million, which missed the Zacks Consensus Estimate of $127 million. Revenues declined around 35% year over year, owing to lower net product sales. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)More on MRNA’s Q1 EarningsModerna currently ...

This quarterly report represents an earnings surprise of 13.70%. A quarter ago, it was expected that this biotechnology company would post a loss of $2.69 per share when it actually produced a loss of $2.50, delivering a surprise of 7.06%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Moderna (MRNA) came out with a quarterly loss of $2.52 per share versus the Zacks Consensus Estimate of a loss of $2.92. This compares to loss of $3.07 per share a year ago. These f ...

Moderna (MRNA) Q1 2025 Earnings Call May 01, 2025 08:00 AM ET Speaker0 Good day, and thank you for standing by. Welcome to the Moderna first quarter '20 '20 '5 conference call. At this time, all participants are in a listen only mode. After the speakers' presentation, there'll be a question and answer session. To ask a question during the session, you need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again. Pl ...

© 2025 Moderna, Inc. All rights reserved. Forward-looking statements and disclaimer First Quarter 2025 Financial Results May 1, 2025 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's ability to drive use of Spikevax and mRESVIA and expand markets for its products; Moderna's 2025 financial framework; Moderna's ability to deliver cost efficiency across the business, including a ...

Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates Reports first quarter revenues of $0.1 billion, GAAP net loss of $(1.0) billion and GAAP EPS of $(2.52) Reiterates 2025 expected revenue range of $1.5 to $2.5 billion and 2025 year-end cash balance of approximately $6 billion Announces reduction of $1.4 to $1.7 billion in estimated GAAP operating costs by 2027 Advancing up to 10 products toward approval, including multiple oncology candidates CAMBRIDGE, MA / ACCESSWIRE / May ...

Financial Data and Key Metrics Changes - The meeting discussed the election of directors and the approval of executive compensation, indicating a stable governance structure and commitment to management accountability [10][13]. - The appointment of Ernst and Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified, reflecting confidence in financial oversight [14][17]. Business Line Data and Key Metrics Changes - The company highlighted a robust pipeline with several dozen products in clinical development across various therapeutic areas, including respiratory viruses and oncology [20][23]. Market Data and Key Metrics Changes - The management emphasized the importance of driving the use of approved vaccines, which is critical for both patient outcomes and shareholder returns [20]. Company Strategy and Development Direction - The company is focused on three key priorities: driving the use of approved vaccines, aiming for the approval of ten products over the next few years, and delivering cost efficiencies across the business [20][21]. - Management expressed confidence in their ability to navigate the regulatory environment by maintaining constructive engagement with regulatory agencies [22]. Management's Comments on Operating Environment and Future Outlook - Management plans to provide a full update on quarterly performance and pipeline developments in the upcoming earnings call, indicating transparency and ongoing communication with investors [19][24]. - The company believes that focusing on science and data will demonstrate the potential of its medicines and their positive impact on patients [22]. Other Important Information - The meeting was conducted with a quorum present, allowing for the official business to proceed smoothly [7][10]. - The company will report final voting results and a current report to the SEC within four business days, ensuring compliance and transparency [17]. Q&A Session Summary Question: What is the status of the product pipeline beyond COVID vaccines? - The company has a robust pipeline with several dozen products in clinical development across various therapeutic areas, with updates to be provided in the upcoming earnings call [20][23]. Question: What actions are being taken to improve stock performance? - The company believes that executing on its three key priorities will deliver returns for shareholders [20]. Question: How is the company addressing the regulatory environment in the U.S.? - Management highlighted a strong record of working with administrations and emphasized the importance of focusing on science and data to demonstrate the potential of their medicines [22].

Group 1: Market Context - During stock-market corrections, investors are encouraged to take advantage of discounted stocks, as bull markets typically follow downturns, leading to potential long-term gains [1] - Companies often trade at steep discounts during corrections due to panic-selling by investors, creating opportunities for savvy investors [1] Group 2: Moderna - Moderna gained prominence by rapidly developing a COVID-19 vaccine but has faced revenue declines and returned to unprofitability as the pandemic recedes [3][8] - The company has made significant clinical advancements, including the approval of a vaccine for respiratory syncytial virus (RSV) and successful phase 3 studies for a combination COVID/influenza vaccine [5] - Moderna targets high unmet medical needs with a late-stage pipeline that includes a cytomegalovirus (CMV) vaccine and a personalized cancer vaccine, showcasing its innovative capabilities in the mRNA vaccine field [6][7] Group 3: Regeneron Pharmaceuticals - Regeneron Pharmaceuticals is experiencing uncertainty due to biosimilar competition for its key product Eylea, despite strong financial results last year [9][10] - The company’s Dupixent, an eczema treatment, has expanded its label to include chronic obstructive pulmonary disease (COPD), potentially adding billions in sales [11] - Regeneron is developing a new formulation of Eylea with a more convenient dosing schedule, which may mitigate losses from biosimilar competition [12] - The company has a promising pipeline in oncology, weight loss, and gene therapy for hearing loss, along with a new dividend and share-buyback program to reward shareholders [12][13]